Search the Newsreel

NRx Pharmaceuticals, Inc. (NRXP) Reports Q2 Loss, Misses Revenue Estimates

NRx Pharmaceuticals, Inc. (NRXP) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to a loss of $0.98 per share a year ago. These figures are adjusted for non-recurring items. This …

Discipline and Rules-Based Execution in BCRX Response

This article provides an AI-driven analysis for Biocryst Pharmaceuticals Inc. (BCRX), highlighting strong sentiment, a mid-channel oscillation pattern, and an exceptional risk-reward setup targeting a 15.0% gain. It details three distinct institutional trading strategies—Position, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis for …

(AUPH) Risk Channels and Responsive Allocation

The article analyzes Aurinia Pharmaceuticals Inc (NASDAQ: AUPH), highlighting a weak near-term sentiment despite potential long-term strength. It details an exceptional 43.3:1 risk-reward setup targeting an 11.7% gain versus 0.3% risk, and provides AI-generated institutional trading strategies for various risk profiles. The analysis includes …

Universal Technical Institute (UTI) Q3 2025 Earnings Report - Results, Call & Slides

DLocal (NASDAQ:DLO) Posts Earnings Results, Meets Expectations

Universal Technical Institute (UTI) Q4 2024 Earnings Report - Results, Call & Slides

SBC Medical Group Holdings (SBC) Stock Reprices As Margins Power Profit Surge

Rhythm Pharmaceuticals EVP, Jennifer Lee, sells $8.9m in stock

Jennifer Lee, EVP of Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM), sold approximately $8.9 million worth of common stock after exercising options for about $997,036. The sale was executed under a Rule 10b5-1 trading plan as the stock trades near its 52-week high and is considered overvalued …

Can Keros Therapeutics (KROS)’s $20M Takeda Pharmaceutical Company Limited (TAK) Milestone Unlock a Billion-Dollar Opportunity?

On July 30, Keros Therapeutics, Inc. (NASDAQ:KROS) triggered a $20 million development milestone payment from its global partner Takeda Pharmaceutical Company Limited (NYSE:TAK). The payout followed the first patient dosed in the Phase 3 ELRiSE MDS clinical trial, evaluating elritercept against epoetin alfa for …

Rhythm Pharmaceuticals (RYTM) EVP exercises 56,601 options and sells 75,834 shares

Jennifer Kayden Lee, EVP of Rhythm Pharmaceuticals (RYTM), exercised 56,601 stock options at prices of $24.29 and $6.80, and subsequently sold 75,834 common shares at $117.3818 per share. These transactions, valued at approximately $8.90 million gross proceeds from sales and $997K in exercise costs, …

Tonix Pharmaceuticals Holding Corp. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:TNXP) 2026-08-14

Tonix Pharmaceuticals Holding Corp. (TNXP) has released its Q2 2026 earnings call presentation. The company reported an EPS of -$2.47, beating estimates by $0.15, and revenue of $13.54M, surpassing estimates by $5.82M with a 577.88% year-over-year increase. The slide deck provides details related to …

Eton Pharmaceuticals (ETON) Stock Reprices Higher After Profit Inflection

Eton Pharmaceuticals (ETON) stock surged 44.3% to US$58.86 after reporting a significant profit inflection in Q2 2026, with net income reaching US$11.6m and EPS of US$0.42 on US$37.6m revenue. This performance has led to increased revenue guidance for 2026 and supports the company's rare …

Bronstein, Gewirtz & Grossman, LLC Is Investigating Banc of California, Inc. (BANC) And Encourages Investors to Connect

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Banc of California, Inc. (NYSE: BANC) following the company's Q2 2026 financial results. Banc of California reported a net loss of $251.3 million, or $1.61 per share, significantly missing analyst …

Thomas Krummel Sells 3,700 Shares of California Water Service Group (NYSE:CWT) Stock

California Water Service Group Director Thomas M. Krummel sold 3,700 shares of the company's common stock at $50.365 per share on August 13, 2026. This transaction was reported in a Form 4 filed with the SEC, reducing Krummel's direct ownership to 20,103.922 shares. The …

Can AbCellera Biologics (ABCL)’s Vertex Pharmaceuticals Incorporated (VRTX) Deal Turn its TCE Platform Into a Breakthrough?

On July 29, AbCellera Biologics Inc. (NASDAQ:ABCL) and Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) announced a strategic collaboration to research, develop, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases. Under the agreement, AbCellera will leverage its proprietary TCE platform to lead discovery, while Vertex will …

DLocal (DLO) Stock Falls As Strong Growth Meets Concentration Risk

SPRY INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that ARS Pharmaceuticals Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit!

Bronstein, Gewirtz and Grossman, LLC has announced a class action lawsuit against ARS Pharmaceuticals Inc. (NASDAQ:SPRY) on behalf of investors who purchased shares between March 9, 2026, and June 24, 2026. The lawsuit alleges that ARS Pharmaceuticals made misleading statements and concealed material adverse …

NASDAQ: ALNY Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) Investors to Contact the Firm

Kessler Topaz Meltzer & Check, LLP is investigating Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) for potential federal securities law violations after the company announced disappointing Q2 2026 financial results. Alnylam significantly lowered its full-year 2026 TTR product sales guidance, causing its stock price to drop …

Calian Group (TSX:CGY) Stock Faces Margin Peak Questions After Record Quarter

Journey Medical (DERM) Stock Eyes Break Even As Emrosi Gains Traction

Is Biohaven (BHVN)’s Latest Regeneron Pharmaceuticals (REGN) Deal a Major Catalyst for its Pipeline?

Two prominent biopharmaceutical names, Biohaven Ltd. (NYSE:BHVN) and Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), are deepening their relationship across oncology. On July 20, Biohaven announced a clinical supply agreement with Regeneron to evaluate the combination of BHV-1530 and Regeneron's cemiplimab (Libtayo) in patients with solid tumors. …

Is Vertex Pharmaceuticals (VRTX) Fairly Valued As Pipeline Catalysts Near?

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Vertex Pharmaceuticals stock has delivered a strong 5 year return, yet current checks suggest the market now prices it roughly in line with its fundamentals rather than …

Perceptive Advisors (NVNO) reports 3.5% beneficial stake via 24,605 warrants

Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. have reported a beneficial ownership of 3.5% in enVVeno Medical Corporation (NVNO) through 24,605 exercisable warrants. This stake represents 24,605 shares of common stock, based on 682,722 shares outstanding as of July …

Westlake Corporation Declares Quarterly Dividend

$0.533 per share dividend declared payable on September 10, 2026 HOUSTON, Aug. 14, 2026 (GLOBE NEWSWIRE) -- The Board of Directors of Westlake Corporation (NYSE: WLK) today declared a regular dividend distribution of $0.533 per share for the second quarter of 2026. This dividend …

Modular Medical, Inc. Q1 FY2027: Net loss $(6.49M), EPS $(1.19) — 10-Q Summary

Modular Medical, Inc. (MODD) reported a net loss of $(6.49M) for Q1 FY2027, an improvement from the prior year, with diluted loss per share at $(1.19). The company's cash and cash equivalents significantly decreased, leading to a flagged going-concern risk due to liquidity issues. …

Westlake Has Paid and Increased Its Dividend for 22 Years

Westlake Corporation (NYSE: WLK) declared a regular second-quarter 2026 cash dividend of $0.533 per share, payable on September 10, 2026, to shareholders of record as of August 25, 2026. The company highlights its 22-year history of consistently paying and increasing its dividend since its …

NuScale Power (NYSE:SMR) Trading Down 4.8% - Should You Sell?

Adagio Medical Receives Nasdaq Listing Deficiency Notice

California Water (CWT) director sells 3,700 shares in open-market trade

California Water Service Group director Thomas M. Krummel sold 3,700 shares of common stock on August 13, 2026, at a price of $50.365 per share in an open market transaction. Following this sale, Krummel directly holds 20,103.922 shares of the company's common stock. The …

EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

EyePoint, Inc. announced the granting of non-statutory stock options to two new employees as inducement awards, in accordance with NASDAQ Listing Rule 5635(c)(4). These options allow the purchase of up to 14,600 shares of common stock, with an exercise price of $14.75 per share, …

ENvue Medical, Inc. SEC Filing (Aug 14, 2026)

ENvue Medical, Inc. has filed a Form 12b-25 Notification of Late Filing for its Quarterly Report on Form 10-Q for the period ended June 30, 2026. The company stated that additional time is needed to prepare, compile, and analyze supporting documentation to complete its …

ICL Group (ICL) Earnings Beat Brings Its Valuation Back Into Focus

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. ICL Group (NYSE:ICL) is back in focus after reporting second quarter 2026 sales of …

Supernus Pharmaceuticals (SUPN) CMO Rubin exercises PSUs and withholds shares for tax

Supernus Pharmaceuticals' Chief Medical Officer, Jonathan Rubin, exercised 750 Performance Share Units (PSUs) on August 12, 2026, converting them into 750 shares of common stock. To cover tax withholding requirements associated with this vesting, 363 shares were withheld by the company at a price …

Eloxx Pharmaceuticals (ELOX) stake hits 9.99% for Samsara affiliate

Investment entities affiliated with Samsara BioCapital and Srinivas Akkaraju have reported significant beneficial ownership in Eloxx Pharmaceuticals (ELOX). Dr. Srinivas Akkaraju holds 9.99% of the common stock, while each Samsara BioCapital-affiliated entity owns 5.0%. This includes common shares and Pre-Funded Warrants subject to a …

Perceptive Advisors (XFOR) reports 8.1% beneficial stake in X4 Pharmaceuticals

Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. have collectively reported an 8.1% beneficial ownership stake in X4 Pharmaceuticals, Inc. This disclosure was made via an amended Schedule 13G filing, indicating shared voting and dispositive power over 8,085,006 shares, including …

Fuller & Thaler (NASDAQ: COLL) reports 5.03% beneficial stake in common stock

Fuller & Thaler Asset Management, Inc. has reported a beneficial ownership of 5.03% in COLLEGIUM PHARMACEUTICAL, INC (COLL) common stock, totaling 1,632,780.71 shares as of June 30, 2026. The firm holds sole voting and dispositive power over these shares, which are held in accounts …